Problem

Biological R&D teams work with heterogeneous data—files, tables, arrays, experimental records, ontologies, code, and notes—but often lack a reliable way to connect those assets, understand their provenance, and reuse them. Lamin describes the core bottleneck as closing the feedback loop across modalities: without context, lineage, and validation, results are difficult to trust, models cannot effectively access data, and teams struggle to govern changes to data in the way software teams govern code. The economic cost is therefore a productivity and reliability tax—duplicated effort, unreproducible analyses, and slower learning—rather than a publicly disclosed dollar figure. The killer use case is biological AI and R&D teams integrating large multimodal datasets, such as combining CRISPR screening results with single-cell RNA-sequencing data while preserving the lineage of datasets, transformations, and models.

Product / Service

Lamin’s core product is LaminDB, an open-source data-management system and lineage-native lakehouse for multimodal and biological data. It lets scientists query, trace, validate, and govern files, tables, arrays, registries, ontologies, and notes across local or cloud storage. Lineage tracks the inputs and outputs of notebooks, functions, scripts, workflows, and agent sessions; schemas and biological registries provide structure; and branching, versioning, permissions, and open standards provide reproducibility and reduce lock-in.

The commercial delivery layer is LaminHub, a SaaS collaboration hub built on LaminDB, with hosted databases, permissions, audit logs, and team features. Lamin offers a free open-data and open-source tier, a $15-per-month Pro plan, a $640-per-month Team plan, and custom enterprise deployments including on-premises installation. The benefit is a shared, queryable memory layer for scientists and AI agents that can scale from individual projects to pharma-scale deployments without forcing customers into a proprietary storage or API stack.

Market

Lamin competes in the intersection of biological R&D data infrastructure, multimodal AI data management, scientific data lakes, and LIMS/ELN software. Its closest named alternatives in public comparison material include Benchling and Sapio LIMS, although Lamin is differentiated by its open-source core, native data lineage, support for non-tabular biological formats, and positioning as infrastructure beneath both research workflows and AI agents rather than solely as a lab-record system.

Lamin was founded in 2022 and appears commercially available rather than merely pre-product: its public materials list paid SaaS and enterprise plans, and the company says it is used by thousands of scientists across academia, biotech, and global pharma, naming organizations including Pfizer and Altos Labs. The open-source LaminDB repository showed 280 stars and more than 5,000 commits in the reviewed snapshot, while the company lists Dimension Capital, Y Combinator, Pillar VC, and Pioneer Fund among its investors. Public materials reviewed do not disclose revenue, so adoption and funding are clearer than the company’s revenue scale.